Support for advanced diagnosis, drug efficacy and safety monitoring for central nervous system diseases

– Broad portfolio of clinically-relevant imaging markers
– Easy comparison with normative dataset of healthy subjects
– Intuitive user interface for in-depth analysis
– Automated reporting with clear-cut results

Support for advanced diagnosis, drug efficacy and safety monitoring for central nervous system diseases

– Broad portfolio of clinically-relevant imaging markers
– Easy comparison with normative dataset of healthy subjects
– Intuitive user interface for in-depth analysis
– Automated reporting with clear-cut results

BENEFITS

CLINICAL

Improves diagnosis, monitoring and likelihood of observing longitudinal changes by eliminating inter- and intra-rater variability by

22%*

COST & TIME

Reduction of image analysis time and cost by

80%**

* Qynapse study – comparison between automated quantification of white matter lesions and expert manual segmentation
** Based on Qynapse estimation of time and cost of segmentation performed by experts